Bavarian Nordic on vaccine candidate: Preclinical data indicates broad protection

Preclinical data on Bavarian Nordic's covid-19 vaccine candidate indicates broad protection, the company reports on Thursday.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

In a press release on Thursday morning, Danish biotech company Bavarian Nordic states that new preclinical trial data indicates that the firm's vaccine candidate against covid-19 also has the ability to induce a high number of neutralizing antibodies against covid variants and mutations.

"We are pleased to confirm the strong antibody response against emerging and more concerning variants of Sars-CoV2 for our covid-19 vaccine candidate," says Bavarian Nordic CEO Paul Chaplin the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs